Functional proteogenomics-Embracing complexity

Seminars in Immunology

Volumn 23, Issue 4, 2011, Pages 235-251

  Sarwal, Minnie M ^a   Sigdel, Tara K ^a   Salomon, Daniel R ^b  

^a STANFORD UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Functional genomics

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MESSENGER RNA; MICRORNA; PHOSPHOPROTEIN; PROTEIN; PROTEOME;

ALTERNATIVE RNA SPLICING; BIOINFORMATICS; CELL NUCLEUS; CELLULAR IMMUNITY; CYTOPLASM; DNA MICROARRAY; EPIGENETICS; EXOME; FUNCTIONAL GENOMICS; FUNCTIONAL PROTEOMICS; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ASSOCIATION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METABOLOME; MICROBIOME; NONHUMAN; ORGAN TRANSPLANTATION; PEPTIDOMICS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; RNA CLEAVAGE; RNA SPLICING; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

GENE EXPRESSION PROFILING; GENE-ENVIRONMENT INTERACTION; GENOMICS; GRAFT REJECTION; GRAFT SURVIVAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY, CELLULAR; INDIVIDUALIZED MEDICINE; MICROARRAY ANALYSIS; MONITORING, PHYSIOLOGIC; ORGAN TRANSPLANTATION; POLYMORPHISM, GENETIC; PROTEOMICS; QUALITY OF HEALTH CARE;

EID: 80054962123     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.08.002     Document Type: Review

References (97)

1. Akalin E., O'Connell P.J. Genomics of chronic allograft injury. Kidney international Supplement 2010, (119):S33-37.
2. Perco P., Oberbauer R. Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics. Seminars in nephrology 2010, 30(5):520-530.
3. Naesens M., Sarwal M.M. Molecular diagnostics in transplantation. Nature reviews Nephrology 2010, 6(10):614-628.
4. Deepak S., Kottapalli K., Rakwal R., Oros G., Rangappa K., Iwahashi H., Real-Time P.C.R., et al. Revolutionizing Detection and Expression Analysis of Genes. Current genomics 2007, 8(4):234-251.
5. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270(5235):467-470.
6. McManus C.J., Graveley B.R. RNA structure and the mechanisms of alternative splicing. Curr Opin Genet Dev 2011.
7. Grigoryev Y.A., Kurian S.M., Nakorchevskiy A.A., Burke J.P., Campbell D., Head S.R., et al. Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes. PloS one 2009, 4(11):e7906.
8. Tchilian E.Z., Beverley P.C. Altered CD45 expression and disease. Trends in immunol 2006, 27(3):146-153.
9. Hartono C., Muthukumar T., Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr opin organ transplant 2010, 15(1):35-41.
10. Shan J., Feng L., Luo L., Wu W., Li C., Li S., et al. MicroRNAs: Potential biomarker in organ transplantation. Transplant immunol 2011, 24(4):210-215.
11. Anglicheau D., Sharma V.K., Ding R., Hummel A., Snopkowski C., Dadhania D., et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Nati Acad Sci USA 2009, 106(13):5330-5335.
12. Zomer A., Vendrig T., Hopmans E.S., van Eijndhoven M., Middeldorp J.M., Pegtel D.M. Exosomes: Fit to deliver small RNA. Commun Integrative Biol 2010, 3(5):447-450.
13. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011.
14. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470(7333):187-197.
15. Hakonarson H., Grant S.F. Planning a genome-wide association study: points to consider. Ann Med 2011.
16. Robinson P.N., Krawitz P., Mundlos S. Strategies for exome and genome sequence data analysis in disease gene discovery projects. Clin Genet 2011.
17. Rivera R.M., Bennett L.B. Epigenetics in humans: an overview. Curr Opin Endocrinol Diabetes Obes 2010, 17(6):493-499.
18. Harris R.A., Wang T., Coarfa C., Nagarajan R.P., Hong C., Downey S.L., et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat biotechnol 2010, 28(10):1097-1105.
19. Altun G., Loring J.F., Laurent L.C. DNA methylation in embryonic stem cells. J Cell Biochem 2010, 109(1):1-6.
20. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462(7271):315-322.
21. Suganuma T., Workman J.L. Signals and combinatorial functions of histone modifications. Annu Rev Biochem 2010.
22. de Zoeten E.F., Wang L., Butler K., Beier U.H., Akimova T., Sai H., et al. Histone deacetylase 6 and heat shock protein 90 control the functions of foxp3+ T-regulatory cells. Mol Cell Biol 2011, 31(10):2066-2078.
23. Akimova T., Ge G., Golovina T., Mikheeva T., Wang L., Riley J.L., et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010, 136(3):348-363.
24. Kurian S.M., Heilman R., Mondala T.S., Nakorchevsky A., Hewel J.A., Campbell D., et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS ONE 2009, 4(7):e6212.
25. Tao R., de Zoeten E.F., Ozkaynak E., Wang L., Li B., Greene M.I., et al. Histone deacetylase inhibitors and transplantation. Curr Opin Immunol 2007, 19(5):589-595.
26. Kinugasa F., Nagatomi I., Nakanishi T., Noto T., Mori H., Matsuoka H., et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transplant immunol 2009, 21(4):198-202.
27. Leng C., Gries M., Ziegler J., Lokshin A., Mascagni P., Lentzsch S., et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp hematol 2006, 34(6):776-787.
28. Kinugasa F., Noto T., Matsuoka H., Urano Y., Sudo Y., Takakura S., et al. Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transplant immunol 2010, 23(1-2):18-23.
29. Venter J.C. A part of the human genome sequence. Science 2003, 299(5610):1183-1184.
30. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003, 4(9):117.
31. Reichelt O., Muller J., von Eggeling F., Driesch D., Wunderlich H., Schubert J., et al. Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry). Urology 2006, 67(3):472-475.
32. Oates J.C., Varghese S., Bland A.M., Taylor T.P., Self S.E., Stanislaus R., et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int 2005, 68(6):2588-2592.
33. Theodorescu D., Wittke S., Ross M.M., Walden M., Conaway M., Just I., et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006, 7(3):230-240.
34. Ye B., Skates S., Mok S.C., Horick N.K., Rosenberg H.F., Vitonis A., et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006, 12(2):432-441.
35. Decramer S., Wittke S., Mischak H., Zurbig P., Walden M., Bouissou F., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006, 12(4):398-400.
36. Schaub S., Rush D., Wilkins J., Gibson I.W., Weiler T., Sangster K., et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004, 15(1):219-227.
37. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250(10):4007-4021.
38. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18(11):2071-2077.
39. Rozanas C.R., Loyland S.M. Capabilities using 2-D DIGE in proteomics research: the new gold standard for 2-D gel electrophoresis. Methods Mol Biol 2008, 441:1-18.
40. Shin I., Zamfir A.D., Ye B. Capabilities Using 2-D DIGE in Proteomics Research: The New Gold Standard for 2-D Gel Electrophoresis. Methods Mol Biol 2008, 441:19-39.
41. Lilley K.S., Friedman D.B. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004, 1(4):401-409.
42. Kondo T., Hirohashi S. Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol 2009, 577:135-154.
43. Tang N., Tornatore P., Weinberger S.R. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004, 23(1):34-44.
44. Friso G., Giacomelli L., Ytterberg A.J., Peltier J.B., Rudella A., Sun Q., et al. In-depth analysis of the thylakoid membrane proteome of Arabidopsis thaliana chloroplasts: new proteins, new functions, and a plastid proteome database. Plant Cell 2004, 16(2):478-499.
45. Qian W.J., Jacobs J.M., Liu T., Camp D.G., Smith R.D Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006, 5(10):1727-1744.
46. Bogdanov B., Smith R.D. Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom Rev 2005, 24(2):168-200.
47. Washburn M.P., Wolters D., Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19(3):242-247.
48. Wolters D.A., Washburn M.P., Yates J.R. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001, 73(23):5683-5690.
49. Sigdel T.K., Kaushal A., Gritsenko M., Norbeck A.D., Qian W.J., Xiao W., et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin Appl 2010, 4(1):32-47.
50. Srivastava S., Srivastava R.G. Proteomics in the forefront of cancer biomarker discovery. J Proteome Res 2005, 4(4):1098-1103.
51. Voshol H., Brendlen N., Muller D., Inverardi B., Augustin A., Pally C., et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res 2005, 4(4):1192-1199.
52. Chen R., Sigdel T.K., Li L., Kambham N., Dudley J.T., Hsieh S.C., et al. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol 2010, 6(9).
53. Vitzthum F., Behrens F., Anderson N.L., Shaw J.H., Proteomics: from basic research to diagnostic application. A review of requirements & needs. J Proteome Res 2005, 4(4):1086-1097.
54. Yokomizo K., Iijima S., Sakai N., Kurihara Y., Hitratsuka N., Nagai K., et al. Urinary protein analysis in pre- and postoperative cancer patients. J Clin Lab Anal 2005, 19(6):253-259.
55. Waikar S.S., Bonventre J.V. Biomarkers for the diagnosis of acute kidney injury. Curr Opin Nephrol Hypertens 2007, 16(6):557-564.
56. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1(11):845-867.
57. Liu T., Qian W.J., Mottaz H.M., Gritsenko M.A., Norbeck A.D., Moore R.J., et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006, 5(11):2167-2174.
58. Jacobs J.M., Adkins J.N., Qian W.J., Liu T., Shen Y., Camp D.G., et al. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 2005, 4(4):1073-1085.
59. Pisitkun T., Shen R.F., Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 2004, 101(36):13368-13373.
60. Thongboonkerd V., Semangoen T., Chutipongtanate S. Enrichment of the basic/cationic urinary proteome using ion exchange chromatography and batch adsorption. J Proteome Res 2007, 6(3):1209-1214.
61. Alban A., Andrew|David S.O., Stephen Olu|Bjorkesten L., Lennart|Andersson C., Christian|Sloge E., Erik|Lewis S., Steve|Currie I. Ian. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3(1):36-44.
62. Sigdel T.K., Lee S., Sarwal M.M. Profiling the proteome in renal transplantation. Proteomics Clin Appl 2011, 5(5-6):269-280.
63. Soderblom E.J., Philipp M., Thompson J.W., Caron M.G., Moseley M.A. Quantitative label-free phosphoproteomics strategy for multifaceted experimental designs. Anal Chem 2011, 83(10):3758-3764.
64. Wright C.A., Howles S., Trudgian D.C., Kessler B.M., Reynard J.M., Noble J.G, et al. Label-free quantitative proteomics reveals differentially regulated proteins influencing urolithiasis. Mol Cell Proteomics 2011.
65. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17(10):994-999.
66. Haqqani A.S., Hutchison J.S., Ward R., Stanimirovic D.B. Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS. J Neurotrauma 2007, 24(1):54-74.
67. Chen R., Brentnall T.A., Pan S., Cooke K., Moyes K.W., Lane Z., et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007, 6(8):1331-1342.
68. DeSouza L.V., Grigull J., Ghanny S., Dube V., Romaschin A.D., Colgan T.J., et al. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007, 6(7):1170-1182.
69. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture: SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1(5):376-386.
70. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive Isobaric Tagging Reagents. Mol Cell Proteomics 2004, 3(12):1154-1169.
71. Griffiths S.D., Burthem J., Unwin R.D., Holyoake T.L., Melo J.V., Lucas G.S., et al. The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol 2007, 36(2):81-89.
72. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006, 9(3):293-348.
73. Siu K.W., DeSouza L.V., Scorilas A., Romaschin A.D., Honey R.J., Stewart R., et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 2009, 8(8):3797-3807.
74. Pichler P., Kocher T., Holzmann J., Mohring T., Ammerer G., Mechtler K. Improved precision of iTRAQ and TMT quantification by an axial extraction field in an Orbitrap HCD cell. Anal Chem 2011, 83(4):1469-1474.
75. Andersen C.A., Gotta S., Magnoni L., Raggiaschi R., Kremer A., Terstappen G.C. Robust MS quantification method for phospho-peptides using 18O/16O labeling. BMC Bioinformatics 2009, 10:141.
76. Siwy J., Mullen W., Golovko I., Franke J., Zurbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011, 5(5-6):367-374.
77. Hu S., Yu T., Xie Y., Yang Y., Li Y., Zhou X., et al. Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics 2007, 4(2):55-64.
78. Barrett T., Troup D.B., Wilhite S.E., Ledoux P., Rudnev D., Evangelista C., et al. NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 2007, 35(Database issue):D760-765.
79. Peng W., Chen J., Jiang Y., Shou Z., Chen Y., Wang H. Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. Nephrology (Carlton) 2008, 13(1):73-79.
80. Peng W., Chen J., Jiang Y., Wu J., Shou Z., He Q., et al. Urinary fractalkine is a marker of acute rejection. Kidney Int 2008, 74(11):1454-1460.
81. Hauser I.A., Spiegler S., Kiss E., Gauer S., Sichler O., Scheuermann E.H., et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005, 16(6):1849-1858.
82. Millan O., Benitez C., Guillen D., Lopez A., Rimola A., Sanchez-Fueyo A., et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 2010, 137(3):337-346.
83. Kirk A.D. Location location, location: regional immune mechanisms critically influence rejection. Nat Med 2002, 8(6):553-555.
84. Ginsburg G.S., McCarthy J.J. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001, 19(12):491-496.
85. Goldfarb-Rumyantzev A.S. Personalized medicine and prediction of outcome in kidney transplant. Am J Kidney Dis 2010, 56(5):817-819.
86. Lampreabe I., Gainza de los Rios F.J., Arrieta Gutierrez A., Jofre-Monseny L., Rodriguez M., Amenabar Iribar J.J., et al. Toward personalized medicine in renal transplantation. Transplant Proc 2010, 42(8):2864-2867.
87. Coto E., Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009, 88(3 Suppl):S62-67.
88. Wavamunno M.D., Chapman J.R. Individualization of immunosuppression: concepts and rationale. Curr Opin Organ Transplant 2008, 13(6):604-608.
89. Hesselink D.A., van Gelder T., van Schaik R.H. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. Pharmacogenomics 2005, 6(4):323-337.
90. Holt K.E., Parkhill J., Mazzoni C.J., Roumagnac P., Weill F.X., Goodhead I., et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi. Nat Genet 2008, 40(8):987-993.
91. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10(1):57-63.
92. Nicholson J.K., Lindon J.C. Systems biology: Metabonomics. Nature 2008, 455(7216):1054-1056.
93. Schauer N., Steinhauser D., Strelkov S., Schomburg D., Allison G., Moritz T., et al. GC-MS libraries for the rapid identification of metabolites in complex biological samples. FEBS Lett 2005, 579(6):1332-1337.
94. Gika H.G., Theodoridis G.A., Wingate J.E., Wilson I.D. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 2007, 6(8):3291-3303.
95. Soga T., Ohashi Y., Ueno Y., Naraoka H., Tomita M., Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003, 2(5):488-494.
96. Butte A.J. Medicine. The ultimate model organism. Science 2008, 320(5874):325-327.
97. Breving K., Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. International J Biochem Cell Biol 2010, 42(8):1316-1329.